33 results on '"Wilson-Robles H"'
Search Results
2. Development, analytical validation, and initial clinical evaluation of a radioimmunoassay for the measurement of soluble CD25 concentrations in canine serum
- Author
-
Buono, A., Lidbury, J.A., Wood, C., Wilson-Robles, H., Dangott, L.J., Allenspach, K., Suchodolski, J.S., and Steiner, J.M.
- Published
- 2019
- Full Text
- View/download PDF
3. Geographical differences in survival of dogs with non‐Hodgkin lymphoma treated with a CHOP based chemotherapy protocol
- Author
-
Wilson‐Robles, H., Budke, C. M., Miller, T., Dervisis, N., Novosad, A., Wright, Z., Thamm, D. H., Vickery, K., Burgess, K., Childress, M., Lori, J., Saba, C., Rau, S., Silver, M., Post, G., Reeds, K., Gillings, S., Schleis, S., Stein, T., Brugmann, B., DeRegis, C., Smrkovski, O., Lawrence, J., and Laver, T.
- Published
- 2017
- Full Text
- View/download PDF
4. In vitro evaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT‐185 and KPT‐335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells
- Author
-
Grayton, J. E., Miller, T., and Wilson‐Robles, H.
- Published
- 2017
- Full Text
- View/download PDF
5. Identification and evaluation of putative tumour-initiating cells in canine malignant melanoma cell lines†
- Author
-
Wilson-Robles, H. M., Daly, M., Pfent, C., and Sheppard, S.
- Published
- 2015
- Full Text
- View/download PDF
6. Neoadjuvant chemotherapy and radiation therapy in veterinary cancer treatment: a review
- Author
-
Wustefeld‐Janssens, B., primary, Smith, L., additional, and Wilson‐Robles, H., additional
- Published
- 2020
- Full Text
- View/download PDF
7. In vitro evaluation of the non-steroidal anti-inflammatory drug, tolfenamic acid, for canine solid tumours
- Author
-
Wilson-Robles, H., Chadalapaka, G., Jutooru, I., Sheppard, S., and Safe, S.
- Published
- 2011
8. T-cell therapy for out-bred canines with spontaneous B-cell non-Hodgkin lymphoma
- Author
-
OʼConner, C., Sheppard, S., Johnson, M., June, C., Craig, S., Lee, D., Champlin, R., Wilson-Robles, H., and Cooper, L.
- Published
- 2011
9. Isolation and characterization of tumour-initiating cells in two canine melanoma cell lines
- Author
-
Daly, M., Sheppard, S., and Wilson-Robles, H.
- Published
- 2011
10. Evaluation of nucleosome concentrations in healthy dogs and dogs with cancer
- Author
-
Wilson-Robles, H, primary, Miller, T, additional, Jarvis, J, additional, Terrell, J, additional, Dewsbury, N, additional, Kelly, T, additional, Herzog, M, additional, Bygott, T, additional, Hardat, N, additional, and Michel, G, additional
- Published
- 2020
- Full Text
- View/download PDF
11. Neoadjuvant chemotherapy and radiation therapy in veterinary cancer treatment: a review.
- Author
-
Wustefeld‐Janssens, B., Smith, L., and Wilson‐Robles, H.
- Subjects
CANCER radiotherapy ,NEOADJUVANT chemotherapy ,CANCER treatment ,EVIDENCE-based medicine ,RADIOTHERAPY - Abstract
Multi‐modality treatment strategies are more becoming commonplace in veterinary oncology practice yet the evidence base is far inferior to what has been generated in people. Surgery is unquestionably the cornerstone of most solid tumour treatment plans but certain scenarios dictate combining surgery with systemic chemotherapy and radiation therapy as an adjunct. By using these in the neoadjuvant setting, one can leverage certain effects of the treatment to improve local disease control, improve overall survival, gain insight into drug efficacy, reduce surgical morbidity and reduce long‐term complications. An unintended consequence of combining therapies is an increased flow of information between members of the care team upfront that in almost all cases leads to improved patient outcomes albeit a difficult metric to quantify. This review sets out to explore some of the principles of neoadjuvant therapies and discuss potential opportunities to expand the evidence base in veterinary medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. In vitroevaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells
- Author
-
Grayton, J. E., primary, Miller, T., additional, and Wilson-Robles, H., additional
- Published
- 2017
- Full Text
- View/download PDF
13. Developing T Cell Cancer Immunotherapy in the Dog with Lymphoma
- Author
-
O'Connor, C. M., primary and Wilson-Robles, H., additional
- Published
- 2014
- Full Text
- View/download PDF
14. Identification and evaluation of putative tumour‐initiating cells in canine malignant melanoma cell lines
- Author
-
Wilson‐Robles, H. M., primary, Daly, M., additional, Pfent, C., additional, and Sheppard, S., additional
- Published
- 2013
- Full Text
- View/download PDF
15. Noninvasive Blood-Based Cancer Detection in Veterinary Medicine.
- Author
-
Flory A and Wilson-Robles H
- Subjects
- Animals, Dogs, Liquid Biopsy methods, Liquid Biopsy veterinary, Neoplasms diagnosis, Neoplasms veterinary, Dog Diseases diagnosis
- Abstract
The past decade has seen incredible advances in blood-based cancer detection in people and in dogs - yet this represents only a glimpse of the benefits these tests can provide to patients. The clinical uses of this technology range from screening asymptomatic individuals for early detection to use as an aid in diagnosis when cancer is suspected, to cancer monitoring both during and after treatment. This article summarizes the benefits of early cancer detection and examines use cases and methods of blood-based cancer detection in dogs, including quantitative, qualitative, and alternative approaches., Competing Interests: Disclosure Dr A. Flory is an employee and shareholder of PetDx. PetDx did not play a role in the study design, decision to publish, or preparation of this article. Dr H. Wilson-Robles is a paid consultant for Volition Veterinary Diagnostic Development (VVDD). VVDD did not play a role in the study design, decision to publish, or preparation of the article., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
16. Monitoring plasma nucleosome concentrations to measure disease response and progression in dogs with hematopoietic malignancies.
- Author
-
Wilson-Robles H, Warry E, Miller T, Jarvis J, Matsushita M, Miller P, Herzog M, Turatsinze JV, Kelly TK, Butera ST, and Michel G
- Subjects
- Male, Humans, Dogs, Animals, Nucleosomes, Thymidine Kinase, Biomarkers, C-Reactive Protein, Neoplasms, Hematologic Neoplasms veterinary, Dog Diseases diagnosis
- Abstract
Background: Hematopoietic malignancies are extremely common in pet dogs and represent nearly 30% of the malignancies diagnosed in this population each year. Clinicians commonly use existing tools such as physical exam findings, radiographs, ultrasound and baseline blood work to monitor these patients for treatment response and remission. Circulating biomarkers, such as prostate specific antigen or carcinoembryonic antigen, can be useful tools for monitoring treatment response and remission status in human cancer patients. To date, there has a been a lack of useful circulating biomarkers available to veterinary oncology patients., Methods: Circulating plasma nucleosome concentrations were evaluated at diagnosis, throughout treatment and during remission monitoring for 40 dogs with lymphoma, acute myelogenous leukemia and multiple myeloma. Additionally, C-reactive protein and thymidine kinase-1 levels were recorded., Results: Plasma nucleosome concentrations were significantly higher at diagnosis and progressive disease than they were when dogs were in remission. All but two dogs had plasma nucleosome concentrations that returned to the low range during treatment. These two dogs had the shortest progression free and overall survival times. Dogs with the highest plasma nucleosome concentrations had a significantly shorter first progression free survival than dogs with lower plasma nucleosome concentrations at diagnosis. Plasma nucleosome concentrations correlated better with disease response and progression than either thymidine kinase or C reactive protein., Conclusions: Plasma nucleosome concentrations can be a useful tool for treatment monitoring and disease progression in dogs with hematopoietic malignancies., Competing Interests: JVT, TK, MH, TB and GM are employees of Belgian Volition, Volition Diagnostics UK ltd & Volition America, which have patents covering Nu. Q technology and are developers of Nu.QTM assays. Volition Veterinary is a joint venture between Belgian Volition and Texas A&M University. HWR is a paid consultant of Volition Veterinary. EW, TM, PM, MM and JJ have no conflicts of interest to declare. Additional salary support for TM was provided by the Fred and Vola Palmer Chair in Comparative Oncology held by HWR. The Palmers did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support for the authors’ salaries (T.M.). This does not alter our adherence to PLoS One policies on sharing data and materials., (Copyright: © 2023 Wilson-Robles et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
17. Esomeprazole induces structural changes and apoptosis and alters function of in vitro canine neoplastic mast cells.
- Author
-
Gould EN, Szule JA, Wilson-Robles H, Steiner JM, Lennon EM, and Tolbert MK
- Subjects
- Rats, Mice, Dogs, Humans, Animals, Proton Pump Inhibitors pharmacology, Proton Pump Inhibitors metabolism, Prospective Studies, Famotidine metabolism, Famotidine pharmacology, Apoptosis, Mast Cells, Esomeprazole pharmacology, Esomeprazole metabolism
- Abstract
Histamine-2 receptor antagonists such as famotidine and proton pump inhibitors such as esomeprazole are commonly used in canine MCT disease, but direct effects on dog MCs have not been evaluated. Omeprazole is a proton pump inhibitor which has been demonstrated to cause structural and functional changes to in vitro murine mast cells (MCs). It has not yet been determined if esomeprazole, the commercially available and commonly prescribed S-isomer of omeprazole, has similar effects. Our primary study objective was to evaluate and compare the effects of acid suppressants (esomeprazole and famotidine) on MC ultrastructure, viability, and function in vitro using both healthy and neoplastic MCs. Murine bone marrow derived mast cells (BMMC), human LAD2, and canine C2 and BR cells, were used for these studies, representing a single healthy (i.e., BMMCs) MC model and multiple neoplastic MC models (i.e., LAD2, C2, BR), respectively. The rat basophilic leukemic (RBL-2H3) and canine B cell lymphoma 17-71 cell lines served as granulocytic and agranulocytic control lines for experiments, respectively. The treatment effect of acid suppressants on MC ultrastructure was assessed via both light and transmission electron microscopy. Differences in MC viability was assessed between groups via MTS-based, colorimetric assays and flow cytometry. Degranulation was assessed by quantification of β-hexosaminidase (i.e., LAD2 and RBL-2H3). Esomeprazole-treated MCs of all lines exhibited dramatic time and concentration-dependent alterations in ultrastructure (i.e., increased vacuolization, compromise of cell membrane), increased apoptosis, and altered degranulation responses in comparison to famotidine and vehicle-treated cells. The canine B cell lymphoma cells consistently exhibited either no significant (i.e., cytotoxicity assays) or greatly diminished treatment responses (i.e., apoptosis) compared to MCs. Esomeprazole, but not famotidine, induces significant cytotoxicity, as well as alterations to cell structure and function to multiple lines of in vitro neoplastic MCs. Continued in vitro work investigating the specific mechanisms by which proton pump inhibitors induce these effects, as well as prospective, in vivo work comparing the treatment effects of acid suppressants on canine MCTs, are warranted., Competing Interests: Conflict of Interest None to disclose., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
18. Feasibility and safety of whole lung irradiation in the treatment of canine appendicular osteosarcoma.
- Author
-
Brehm A, Wilson-Robles H, Miller T, Jarvis J, and Deveau M
- Subjects
- Animals, Dogs, Feasibility Studies, Humans, Lung, Bone Neoplasms drug therapy, Bone Neoplasms radiotherapy, Bone Neoplasms veterinary, Dog Diseases drug therapy, Dog Diseases radiotherapy, Osteosarcoma drug therapy, Osteosarcoma radiotherapy, Osteosarcoma veterinary
- Abstract
Whole lung irradiation (WLI) has been used successfully in humans as an adjuvant treatment for osteosarcoma. The aim of this study is to describe the feasibility and safety of WLI in dogs with appendicular osteosarcoma. Twelve client-owned dogs with appendicular osteosarcoma that had successfully completed amputation and four doses of carboplatin without evidence of gross metastasis were enrolled in this prospective clinical trial. Ten once-daily fractions of 1.75 Gy were administered to the planning target volume encompassing the lungs. Overall, WLI was well tolerated in these patients. No dogs developed symptoms of pneumonitis or pulmonary fibrosis. Haematopoietic toxicity evaluated during radiation therapy was found to be mild. The median disease free interval for WLI treated dogs was not significantly different than the median DFI for a group of historic control dogs (376 days for WLI treated dogs versus 304.5 days for control dogs; p = 0.5461). Although no significant improvement in outcome was observed with this study, WLI appears to be safe in dogs and warrants further investigation to characterize the efficacy and toxicity., (© 2021 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
19. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.
- Author
-
Kochat V, Raman AT, Landers SM, Tang M, Schulz J, Terranova C, Landry JP, Bhalla AD, Beird HC, Wu CC, Jiang Y, Mao X, Lazcano R, Gite S, Ingram DR, Yi M, Zhang J, Keung EZ, Scally CP, Roland CL, Hunt KK, Feig BW, Futreal PA, Hwu P, Wang WL, Lazar AJ, Slopis JM, Wilson-Robles H, Wiener DJ, McCutcheon IE, Wustefeld-Janssens B, Rai K, and Torres KE
- Subjects
- Animals, Biomarkers, Tumor, Cell Cycle Proteins antagonists & inhibitors, Cell Differentiation genetics, Cell Line, Tumor, Dogs, Enhancer Elements, Genetic genetics, Epigenesis, Genetic genetics, Homeodomain Proteins genetics, Humans, Mice, Mice, Transgenic, Mutation, Nerve Sheath Neoplasms pathology, Neural Crest pathology, Peripheral Nervous System Neoplasms pathology, Species Specificity, Transcription Factors antagonists & inhibitors, Transcription Factors genetics, Xenograft Model Antitumor Assays, Zebrafish, Nerve Sheath Neoplasms drug therapy, Nerve Sheath Neoplasms genetics, Peripheral Nervous System Neoplasms drug therapy, Peripheral Nervous System Neoplasms genetics, Polycomb Repressive Complex 2 genetics
- Abstract
Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that frequently harbor genetic alterations in polycomb repressor complex 2 (PRC2) components-SUZ12 and EED. Here, we show that PRC2 loss confers a dedifferentiated early neural-crest phenotype which is exclusive to PRC2-mutant MPNSTs and not a feature of neurofibromas. Neural crest phenotype in PRC2 mutant MPNSTs was validated via cross-species comparative analysis using spontaneous and transgenic MPNST models. Systematic chromatin state profiling of the MPNST cells showed extensive epigenomic reprogramming or chromatin states associated with PRC2 loss and identified gains of active enhancer states/super-enhancers on early neural crest regulators in PRC2-mutant conditions around genomic loci that harbored repressed/poised states in PRC2-WT MPNST cells. Consistently, inverse correlation between H3K27me3 loss and H3K27Ac gain was noted in MPNSTs. Epigenetic editing experiments established functional roles for enhancer gains on DLX5-a key regulator of neural crest phenotype. Consistently, blockade of enhancer activity by bromodomain inhibitors specifically suppressed this neural crest phenotype and tumor burden in PRC2-mutant PDXs. Together, these findings reveal accumulation of dedifferentiated neural crest like state in PRC2-mutant MPNSTs that can be targeted by enhancer blockade., (© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.)
- Published
- 2021
- Full Text
- View/download PDF
20. Characterizing circulating nucleosomes in the plasma of dogs with lymphoma.
- Author
-
Dolan C, Miller T, Jill J, Terrell J, Kelly TK, Bygott T, and Wilson-Robles H
- Subjects
- Animals, Case-Control Studies, Dogs, Lymphoma, B-Cell blood, Lymphoma, T-Cell blood, Dog Diseases blood, Lymphoma, B-Cell veterinary, Lymphoma, T-Cell veterinary, Nucleosomes
- Abstract
Background: Nucleosomes consist of DNA wrapped around a histone octamer core like beads on a string so that DNA can be condensed as chromatin into chromosomes. Diseases such as cancer or inflammation lead to cell death where chromatin is fragmentated and released as mononucleosomes into the blood. The Nu.Q™ H3.1 assay measures total nucleosome concentration in plasma of humans and has been used to detect and identify cancer even at early stages. The objectives of this study were to determine if nucleosome levels could be used to distinguish between healthy dogs and dogs with various stages of lymphoma (LSA) using the Nu.Q™ H3.1 assay. A total of 126 dogs diagnosed with LSA and 134 healthy controls were recruited for this study. Plasma was collected from each dog and stored in K2-EDTA tubes. The LSA patient samples were recruited from TAMU or purchased from various biobanks. All control cases were recruited from TAMU., Results: Dogs with LSA had an approximately 7-fold increase in their plasma nucleosome concentrations compared to controls (AUC 87.8%). Nucleosome concentrations increased with cancer stage and dogs with B cell lymphomas had significantly higher nucleosome concentrations than dogs with T cell lymphomas., Conclusions: The Nu.Q™ H3.1 assay was able to reliably detect elevated nucleosome concentrations in the plasma of dogs with LSA. Furthermore, it appears that nucleosomes are useful for differentiating cancer from healthy individuals in canines., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
21. Characterizing circulating nucleosomes in the plasma of dogs with hemangiosarcoma.
- Author
-
Wilson-Robles H, Miller T, Jarvis J, Terrell J, Kelly TK, Bygott T, and Bougoussa M
- Subjects
- Animals, Case-Control Studies, Disease Progression, Dog Diseases diagnosis, Dogs, Female, Hemangiosarcoma blood, Hemangiosarcoma diagnosis, Male, Dog Diseases blood, Hemangiosarcoma veterinary, Nucleosomes
- Abstract
Background: Nucleosomes consist of DNA wrapped around a histone octamer core like thread on a spool to condense DNA as chromatin into chromosomes. Diseases such as cancer or inflammation lead to cell death, chromatin fragmentation and release of nucleosomes into the blood. The Nu.Q™ platform measures circulating nucleosomes in the blood of humans that result from disease and has been used to detect and identify cancer even at early stages. The objectives of this study are to quantify and better characterize nucleosomes in dogs with various stages of hemangiosarcoma (HSA) using this ELISA-based assay. Samples from 77 dogs with a confirmed diagnosis of hemangiosarcoma and 134 healthy controls were utilized for this study. The HSA samples were recruited from the Texas A&M University Small Animal Clinic (TAMU-SAC) or purchased from biobanks. All control samples were recruited from the TAMU-SAC., Results: Dogs with hemangiosarcoma had a 6.6-fold increase in their median plasma nucleosome concentrations compared to controls (AUC 92.9 %). Elevated nucleosome concentrations were seen at all stages of disease and nucleosome concentrations increased with the stage of the disease., Conclusions: Plasma nucleosome concentrations are a reliable way to differentiate dogs with hemangiosarcoma from healthy dogs. Further testing is underway to better characterize cancer associated HSA circulating nucleosomes and optimize future diagnostics for canine HSA detection.
- Published
- 2021
- Full Text
- View/download PDF
22. Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs.
- Author
-
LeBlanc AK, Mazcko CN, Cherukuri A, Berger EP, Kisseberth WC, Brown ME, Lana SE, Weishaar K, Flesner BK, Bryan JN, Vail DM, Burton JH, Willcox JL, Mutsaers AJ, Woods JP, Northrup NC, Saba C, Curran KM, Leeper H, Wilson-Robles H, Wustefeld-Janssens BG, Lindley S, Smith AN, Dervisis N, Klahn S, Higginbotham ML, Wouda RM, Krick E, Mahoney JA, London CA, Barber LG, Balkman CE, McCleary-Wheeler AL, Suter SE, Martin O, Borgatti A, Burgess K, Childress MO, Fidel JL, Allstadt SD, Gustafson DL, Selmic LE, Khanna C, and Fan TM
- Subjects
- Amputation, Surgical, Animals, Bone Neoplasms genetics, Bone Neoplasms mortality, Carboplatin administration & dosage, Chemotherapy, Adjuvant, Combined Modality Therapy veterinary, Dog Diseases mortality, Dogs, Osteosarcoma genetics, Osteosarcoma mortality, Prospective Studies, Signal Transduction drug effects, Sirolimus pharmacology, Survival Rate, TOR Serine-Threonine Kinases metabolism, Treatment Outcome, Bone Neoplasms therapy, Bone Neoplasms veterinary, Dog Diseases therapy, Osteosarcoma therapy, Osteosarcoma veterinary, Pets, Sirolimus administration & dosage
- Abstract
Purpose: The mTOR pathway has been identified as a key nutrient signaling hub that participates in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is biologically achievable with sirolimus, and might slow the outgrowth of distant metastases. In this study, pet dogs with appendicular osteosarcoma were leveraged as high-value biologic models for pediatric osteosarcoma, to assess mTOR inhibition as a therapeutic strategy for attenuating metastatic disease progression., Patients and Methods: A total of 324 pet dogs diagnosed with treatment-naïve appendicular osteosarcoma were randomized into a two-arm, multicenter, parallel superiority trial whereby dogs received amputation of the affected limb, followed by adjuvant carboplatin chemotherapy ± oral sirolimus therapy. The primary outcome measure was disease-free interval (DFI), as assessed by serial physical and radiologic detection of emergent macroscopic metastases; secondary outcomes included overall 1- and 2-year survival rates, and sirolimus pharmacokinetic variables and their correlative relationship to adverse events and clinical outcomes., Results: There was no significant difference in the median DFI or overall survival between the two arms of this trial; the median DFI and survival for standard-of-care (SOC; defined as amputation and carboplatin therapy) dogs was 180 days [95% confidence interval (CI), 144-237] and 282 days (95% CI, 224-383) and for SOC + sirolimus dogs, it was 204 days (95% CI, 157-217) and 280 days (95% CI, 252-332), respectively., Conclusions: In a population of pet dogs nongenomically segmented for predicted mTOR inhibition response, sequentially administered adjuvant sirolimus, although well tolerated when added to a backbone of therapy, did not extend DFI or survival in dogs with appendicular osteosarcoma., (©2021 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
23. Comprehensive live-cell imaging analysis of cryptotanshinone and synergistic drug-screening effects in various human and canine cancer cell lines.
- Author
-
Bittner ML, Lopes R, Hua J, Sima C, Datta A, and Wilson-Robles H
- Subjects
- Animals, Apoptosis drug effects, Cell Line, Tumor, Cell Survival drug effects, Dogs, Early Detection of Cancer methods, Humans, Neoplasms metabolism, STAT3 Transcription Factor antagonists & inhibitors, Salvia miltiorrhiza metabolism, Signal Transduction drug effects, Neoplasms drug therapy, Phenanthrenes metabolism, Phenanthrenes pharmacology
- Abstract
Background: Several studies have highlighted both the extreme anticancer effects of Cryptotanshinone (CT), a Stat3 crippling component from Salvia miltiorrhiza, as well as other STAT3 inhibitors to fight cancer., Methods: Data presented in this experiment incorporates 2 years of in vitro studies applying a comprehensive live-cell drug-screening analysis of human and canine cancer cells exposed to CT at 20 μM concentration, as well as to other drug combinations. As previously observed in other studies, dogs are natural cancer models, given to their similarity in cancer genetics, epidemiology and disease progression compared to humans., Results: Results obtained from several types of human and canine cancer cells exposed to CT and varied drug combinations, verified CT efficacy at combating cancer by achieving an extremely high percentage of apoptosis within 24 hours of drug exposure., Conclusions: CT anticancer efficacy in various human and canine cancer cell lines denotes its ability to interact across different biological processes and cancer regulatory cell networks, driving inhibition of cancer cell survival., Competing Interests: The authors have declared no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
24. Evaluation of nucleosome concentrations in healthy dogs and dogs with cancer.
- Author
-
Wilson-Robles H, Miller T, Jarvis J, Terrell J, Dewsbury N, Kelly T, Herzog M, Bygott T, Hardat N, and Michel G
- Subjects
- Animals, Dogs, Enzyme-Linked Immunosorbent Assay instrumentation, Enzyme-Linked Immunosorbent Assay methods, Feasibility Studies, Female, Lymphoma blood, Male, Reproducibility of Results, Lymphoma diagnosis, Lymphoma veterinary, Nucleosomes, Reagent Kits, Diagnostic veterinary
- Abstract
Introduction: Nucleosomes consist of small fragments of DNA wrapped around a histone octamer core. Diseases such as cancer or inflammation lead to cell death, which causes fragmentation and release of nucleosomes into the blood. The Nu.Q™ technology measures circulating nucleosome levels and exploits the different compositions of cancer derived nucleosomes in blood to detect and identify cancer even at early stages. The objectives of this study are to identify the optimal sample type for the Nu.Q™ H3.1 assay and to determine if it can accurately detect nucleosomes in the blood of healthy canines as well as those with cancer., Materials and Methods: Blood samples from healthy canine volunteers as well as dogs newly diagnosed with lymphoma were used. The blood was processed at a variety of times under a variety of conditions to determine the most reliable sample type and conditions, and to develop an appropriate processing strategy to ensure reliably accurate results., Results: Nucleosomes could be detected using a variety of sample collection and processing protocols. Nucleosome signals were highest in EDTA plasma and serum samples and most consistent in plasma. Samples should be processed within an hour of collection. Experiments showed that samples were able to withstand several freeze thaw cycles. Processing time and tcollection tube type did affect nucleosome detection levels. Finally, significantly elevated concentrations of nucleosomes were seen in a small cohort of dogs that had been newly diagnosed with lymphoma., Conclusions: When samples are collected and processed appropriately, the Nu.Q™ platform can reliably detect nucleosomes in the plasma of dogs. Further testing is underway to validate and optimize the Nu.Q™ platform for veterinary use., Competing Interests: I have read the Journal's policy and the authors of this manuscript have the following competing interests: JT, ND, TK, MH, TB NH and GM are employees of Belgian Volition & Volition America, which have patents covering Nu.Q technology and are developers of Nu.Q™ assays. Volition Veterinary is a joint venture between Belgian Volition and Texas A&M University. HWR is a paid consultant of Volition Veterinary. TM and JJ have no conflicts of interest to declare. Additional salary support for TM was provided by the Fred and Vola Palmer Chair in Comparative Oncology held by HWR. The Palmers did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support for the authors’ salaries (T.M.). This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2020
- Full Text
- View/download PDF
25. The Global Initiative for Veterinary Cancer Surveillance (GIVCS): Report of the first meeting and future perspectives.
- Author
-
Pinello KC, Queiroga FLPG, de Matos A, Santos A, Ribeiro JN, Guscetti F, Palmieri C, Soberano M, Momanyi K, Torres JR, Killick D, Radford A, Wilson-Robles H, de Carvalho JP, Tedardi MV, and Dagli MLZ
- Subjects
- Animals, Dogs, Dog Diseases, Neoplasms diagnosis, Neoplasms epidemiology, Neoplasms veterinary
- Published
- 2020
- Full Text
- View/download PDF
26. Treatment of feline injection-site sarcoma with surgery and iridium-192 brachytherapy: retrospective evaluation of 22 cats.
- Author
-
Bloch J, Rogers K, Walker M, Dawson J, and Wilson-Robles H
- Subjects
- Animals, Brachytherapy veterinary, Cats, Postoperative Complications veterinary, Retrospective Studies, Cat Diseases radiotherapy, Cat Diseases surgery, Fibrosarcoma radiotherapy, Fibrosarcoma surgery, Fibrosarcoma veterinary, Injections adverse effects, Injections veterinary, Iridium Radioisotopes therapeutic use, Soft Tissue Neoplasms radiotherapy, Soft Tissue Neoplasms surgery, Soft Tissue Neoplasms veterinary
- Abstract
Objectives: The aim of this retrospective descriptive study was to determine the effectiveness of using iridium implants in addition to surgery in cats with feline injection-site sarcomas (FISSs) in terms of time to progression and disease-specific survival and to identify prognostic factors for patient outcome., Methods: Medical records of cats presented at our institution with FISS were reviewed. Inclusion criteria included histologic diagnosis of a tumor type associated with post-injection neoplastic development, tumor located at a site associated with vaccination, no other therapies prior to the administration of brachytherapy with the exception of surgery and adequate follow-up data., Results: Twenty-two cats with FISS were treated with surgery and brachytherapy delivered by postoperative iridium-192 interstitial implants. Radiation doses ranged from 4000 to 6000 cGy (median dose 5079.55 cGy), with most doses delivered over 7 days. The median number of surgeries prior to brachytherapy was one (range 1-4). The complications associated with postoperative brachytherapy were typically mild, although four cats developed more severe complications. The median time to progression for all cats was 619 days and disease-specific survival time for all cats was 1242 days. The 1 and 2 year tumor-free rates in these cats were 63.6% and 40.9%, respectively. The local failure rate was 54.5% and the distant failure rate was 13.6% due to lung metastasis. There was a significant difference in time to progression of cats that had a single surgery performed prior to brachytherapy and those that had multiple surgeries (undefined vs 310 days; P = 0.01). There were no other statistically significant identified prognostic factors., Conclusions and Relevance: These data suggest that the addition of brachytherapy postoperatively in cats with FISS was well tolerated and is comparable to other forms of adjuvant therapy.
- Published
- 2020
- Full Text
- View/download PDF
27. Characterization of five newly derived canine osteosarcoma cell lines.
- Author
-
Wilson-Robles H, Franks K, Pool R, and Miller T
- Subjects
- Adipogenesis, Alkaline Phosphatase biosynthesis, Animals, Antineoplastic Agents pharmacology, Cell Proliferation, Chondrogenesis, Cisplatin pharmacology, Culture Media, Dog Diseases pathology, Dogs, Female, Heterografts metabolism, Mice, Neoplasm Invasiveness, Neoplasm Transplantation, Osteogenesis, Osteosarcoma metabolism, Cell Line, Tumor cytology, Cell Line, Tumor drug effects, Cell Line, Tumor metabolism, Dog Diseases metabolism, Osteosarcoma veterinary
- Abstract
Background: Canine and human osteosarcomas (OS) are notably similar and have a high rate of metastasis. There is a poor understanding of the tumor development process, predisposing causes, and varying levels of aggression among different cell lines. By characterizing newly developed canine osteosarcoma cell lines, treatments for people and pets can be developed. Of the seven subtypes of OS, three are represented in this group: osteoblastic (the most common), fibroblastic, and giant cell variant. To our knowledge, there are no other giant cell variant canine OS cell lines in the published literature and only one canine fibroblastic osteosarcoma cell line. Understanding the differences between the histologic subtypes in dogs will help to guide comparative research., Results: Alkaline phosphatase expression was ubiquitous in all cell lines tested and invasiveness was variable between the cell lines tested. Invasiveness and oxidative damage were not correlated with in vivo growth rates, where TOT grew the fastest and had the higher percentage of mice with metastatic lesions. TOL was determined to be the most chemo-resistant during cisplatin chemotherapy while TOM was the most chemo-sensitive., Conclusions: Further comparisons and studies using these cell lines may identify a variety of characteristics valuable for understanding the disease process and developing treatments for osteosarcoma in both species. Some of this data was presented as a poster by KMF at the August 5th, 2017 National Veterinary Scholars Program in Bethesda, MA. Characterization of 5 newly generated canine osteosarcoma cell lines. Kelli Franks, Tasha Miller, Heather Wilson-Robles.
- Published
- 2019
- Full Text
- View/download PDF
28. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
- Author
-
Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, Weishaar K, London C, Kisseberth W, Krick E, Vail D, Childress M, Bryan JN, Barber L, Ehrhart EJ, Kent M, Fan T, Kow K, Northup N, Wilson-Robles H, Tomaszewski J, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, and Pommier Y
- Subjects
- Animals, Antineoplastic Agents chemistry, Bone Marrow drug effects, Clinical Trials as Topic, DNA Topoisomerases, Type I metabolism, Disease Models, Animal, Dogs, Drug Monitoring, Lymphoma metabolism, Lymphoma pathology, Maximum Tolerated Dose, Molecular Targeted Therapy, Topoisomerase I Inhibitors chemistry, Antineoplastic Agents pharmacology, Lymphoma drug therapy, Topoisomerase I Inhibitors pharmacology
- Abstract
Purpose: Only one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved, the camptothecins with irinotecan and topotecan widely used. Because of their limitations (chemical instability, drug efflux-mediated resistance, and diarrhea), novel TOP1 inhibitors are warranted. Indenoisoquinoline non-camptothecin topoisomerase I (TOP1) inhibitors overcome chemical instability and drug resistance that limit camptothecin use. Three indenoisoquinolines, LMP400 (indotecan), LMP776 (indimitecan), and LMP744, were examined in a phase I study for lymphoma-bearing dogs to evaluate differential efficacy, pharmacodynamics, toxicology, and pharmacokinetics., Experimental Design: Eighty-four client-owned dogs with lymphomas were enrolled in dose-escalation cohorts for each indenoisoquinoline, with an expansion phase for LMP744. Efficacy, tolerability, pharmacokinetics, and target engagement were determined., Results: The MTDs were 17.5 mg/m
2 for LMP 776 and 100 mg/m2 for LMP744; bone marrow toxicity was dose-limiting; up to 65 mg/m2 LMP400 was well-tolerated and MTD was not reached. None of the drugs induced notable diarrhea. Sustained tumor accumulation was observed for LMP744; γH2AX induction was demonstrated in tumors 2 and 6 hours after treatment; a decrease in TOP1 protein was observed in most lymphoma samples across all compounds and dose levels, which is consistent with the fact that tumor response was also observed at low doses LMP744. Objective responses were documented for all indenoisoquinolines; efficacy (13/19 dogs) was greatest for LMP744., Conclusions: These results demonstrate proof-of-mechanism for indenoisoquinoline TOP1 inhibitors supporting their further clinical development. They also highlight the value of the NCI Comparative Oncology Program (https://ccr.cancer.gov/Comparative-Oncology-Program) for evaluating novel therapies in immunocompetent pets with cancers., (©2018 American Association for Cancer Research.)- Published
- 2018
- Full Text
- View/download PDF
29. Removal of hemangiosarcoma cells from canine blood with a cell salvage system and leukocyte reduction filter.
- Author
-
Ciepluch B, Wilson-Robles H, Levine G, Smith R, Wright GA, Miller T, O'Brien MT, and Thieman Mankin KM
- Subjects
- Animals, Disease Models, Animal, Dogs, Filtration veterinary, Hemangiosarcoma blood, Hemangiosarcoma pathology, Leukocyte Reduction Procedures methods, Operative Blood Salvage methods, Hemangiosarcoma veterinary, Leukocyte Reduction Procedures veterinary, Operative Blood Salvage veterinary
- Abstract
Objective: To determine the ability of an intraoperative cell salvage (IOCS) system and a leukocyte reduction filter (LRF) to remove hemangiosarcoma (HSA) cells from canine blood., Study Design: Cultured HSA cells were added to canine blood to simulate intraoperative hemorrhage and address hemoabdomen from ruptured splenic HSA. The blood/HSA cell mixture was processed through an IOCS, followed by LRF processing., Sample Population: Whole blood from 3 healthy dogs combined with cultured HSA cells., Methods: The ability of quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), multiparameter flow cytometry, and cytologic examination to detect 50 HSA cells per milliliter of culture media was confirmed. RT-PCR, multiparameter flow cytometry, and cytologic examination were used to determine the presence of cultured HSA cells at 4 points during processing., Results: HSA cells were found in all control samples and in all samples after IOCS but prior to LRF processing with all 3 cell detection methods. HSA cells were not found after IOCS/LRF processing with all 3 cell detection methods., Conclusion: IOCS combined with LRF processing is able to remove cultured HSA cells from canine blood. The addition of LRF to IOCS may allow application of IOCS in dogs with HSA., Clinical Significance: A combination of IOCS and LRF processing may provide an alternative to allogeneic blood transfusion in dogs with hemoabdomen due to HSA., (© 2017 The American College of Veterinary Surgeons.)
- Published
- 2018
- Full Text
- View/download PDF
30. Oncology of Reptiles: Diseases, Diagnosis, and Treatment.
- Author
-
Christman J, Devau M, Wilson-Robles H, Hoppes S, Rech R, Russell KE, and Heatley JJ
- Subjects
- Animals, Neoplasms diagnosis, Neoplasms therapy, Neoplasms veterinary, Reptiles
- Abstract
Based on necropsy review, neoplasia in reptiles has a comparable frequency to that of mammals and birds. Reptile neoplasia is now more frequently diagnosed in clinical practice based on increased use of advanced diagnostic techniques and improvements in reptilian husbandry allowing greater longevity of these species. This article reviews the current literature on neoplasia in reptiles, and focuses on advanced diagnostics and therapeutic options for reptilian patientssuffering neoplastic disease. Although most applied clinical reptile oncology is translated from dog and cat oncology, considerations specific to reptilian patients commonly encountered in clinical practice (turtles, tortoises, snakes, and lizards) are presented., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
31. A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.
- Author
-
Saba C, Paoloni M, Mazcko C, Kisseberth W, Burton JH, Smith A, Wilson-Robles H, Allstadt S, Vail D, Henry C, Lana S, Ehrhart EJ, Charles B, Kent M, Lawrence J, Burgess K, Borgatti A, Suter S, Woods P, Gordon I, Vrignaud P, Khanna C, and LeBlanc AK
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Benzamides therapeutic use, Breast Neoplasms drug therapy, Dogs, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Male, Maximum Tolerated Dose, Poly(ADP-ribose) Polymerase Inhibitors pharmacokinetics, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, Triple Negative Breast Neoplasms drug therapy, Antineoplastic Agents pharmacokinetics, Benzamides pharmacokinetics, Neoplasms drug therapy, Neoplasms veterinary
- Abstract
Development of iniparib as an anti-cancer agent was hindered in part by lingering questions regarding its mechanism of action, the activity of its metabolites, and their potential accumulation in tumors. Due to strong similarities in metabolism of iniparib between humans and dogs, a veterinary clinical trial in pet dogs with spontaneous cancers was designed to answer specific questions pertaining to pharmacokinetic exposures and tolerability of iniparib. Dogs were treated with iniparib alone and in combination with carboplatin chemotherapy. Iniparib doses ranged between 10-70 mg/kg intravenously (IV). Plasma, tumor and normal tissue samples were collected before and at various time points scheduled after exposure for pharmacokinetic and biologic analysis. The primary endpoints included characterization of dose-limiting toxicities (DLT) and determination of the drug exposures that could be achieved in both normal and tumor tissues. Nineteen dogs were treated. DLT included fever, anorexia, diarrhea, neutropenia, and thrombocytopenia; most effects were attributable to carboplatin based on the timing of adverse event onset. The maximum tolerated dose (MTD) of iniparib was not identified. Moderate to high variability in plasma exposure was noted for iniparib and all metabolites between animals. When quantifiable, iniparib and metabolite plasma:tumor ratios were < 0.088 and <1.7, respectively. In this study, iniparib was well tolerated as a single agent and in combination with carboplatin over a range of doses. However, clinically relevant concentrations of the parent drug and selected metabolites were not detectable in canine tumor tissues at any studied dose, thus eliminating expectations for clinical responses in dogs or humans. Negative clinical trials in humans, and the uncertainties of its mechanism of action, ultimately led to the decision to stop clinical development of the drug. Nevertheless, the questions that can be asked and answered within the comparative oncology approach are evident from this successfully executed comparative clinical trial and exemplify the value of such studies in drug development.
- Published
- 2016
- Full Text
- View/download PDF
32. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.
- Author
-
London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, and Post G
- Subjects
- Administration, Metronomic, Amputation, Surgical, Animals, Bone Neoplasms veterinary, Diarrhea etiology, Disease-Free Survival, Dog Diseases drug therapy, Dogs, Drug Therapy, Combination, Female, Indoles adverse effects, Kaplan-Meier Estimate, Male, Neutropenia etiology, Osteosarcoma veterinary, Prospective Studies, Pyrroles adverse effects, Regression Analysis, Treatment Outcome, Bone Neoplasms drug therapy, Carboplatin therapeutic use, Cyclophosphamide administration & dosage, Indoles administration & dosage, Osteosarcoma drug therapy, Piroxicam administration & dosage, Pyrroles administration & dosage
- Abstract
Background: We hypothesized that the addition of toceranib to metronomic cyclophosphamide/piroxicam therapy would significantly improve disease-free interval (DFI) and overall survival (OS) in dogs with appendicular osteosarcoma (OSA) following amputation and carboplatin chemotherapy., Methods and Findings: This was a randomized, prospective clinical trial in which dogs with OSA free of gross metastatic disease (n = 126) received carboplatin chemotherapy (4 doses) following amputation. On study entry, dogs were randomized to receive piroxicam/cyclophosphamide with or without toceranib (n = 63 each) after completing chemotherapy. Patient demographics were not significantly different between both groups. During or immediately following carboplatin chemotherapy, 32 dogs (n = 13 toceranib; n = 19 control) developed metastatic disease, and 13 dogs left the study due to other medical conditions or owner preference. Following carboplatin chemotherapy, 81 dogs (n = 46 toceranib; n = 35 control) received the metronomic treatment; 35 dogs (n = 20 toceranib; n = 15 control) developed metastatic disease during the maintenance therapy, and 26 dogs left the study due to other medical conditions or owner preference. Nine toceranib-treated and 11 control dogs completed the study without evidence of metastatic disease 1-year following amputation. Toceranib-treated dogs experienced more episodes of diarrhea, neutropenia and weight loss than control dogs, although these toxicities were low-grade and typically resolved with supportive care. More toceranib-treated dogs (n = 8) were removed from the study for therapy-associated adverse events compared to control dogs (n = 1). The median DFI for control and toceranib treated dogs was 215 and 233 days, respectively (p = 0.274); the median OS for control and toceranib treated dogs was 242 and 318 days, respectively (p = 0.08). The one year survival rate for control dogs was 35% compared to 38% for dogs receiving toceranib., Conclusions: The addition of toceranib to metronomic piroxicam/cyclophosphamide therapy following amputation and carboplatin chemotherapy did not improve median DFI, OS or the 1-year survival rate in dogs with OSA.
- Published
- 2015
- Full Text
- View/download PDF
33. Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells.
- Author
-
Zhang S, Kim K, Jin UH, Pfent C, Cao H, Amendt B, Liu X, Wilson-Robles H, and Safe S
- Subjects
- 3' Untranslated Regions genetics, Animals, Benzofurans pharmacology, Cell Line, Tumor, Female, Humans, Mice, Mice, Nude, Oligonucleotides genetics, Oligonucleotides pharmacology, Polychlorinated Dibenzodioxins pharmacology, RNA Interference, RNA, Messenger genetics, RNA, Messenger metabolism, RNA, Small Interfering, Receptors, Aryl Hydrocarbon genetics, Receptors, Aryl Hydrocarbon metabolism, Receptors, Estrogen deficiency, SOXC Transcription Factors metabolism, Breast Neoplasms pathology, Lung Neoplasms secondary, MicroRNAs metabolism, Receptors, Aryl Hydrocarbon agonists
- Abstract
The aryl hydrocarbon receptor (AHR) was initially identified as a receptor that bound 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related environmental toxicants; however, there is increasing evidence that the AHR is an important new drug target for treating multiple diseases including breast cancer. Treatment of estrogen receptor (ER)-negative MDA-MB-231 and BT474 breast cancer cells with TCDD or the selective AHR modulator 6-methyl-1,3,-trichlorodibenzofuran (MCDF) inhibited breast cancer cell invasion in a Boyden chamber assay. These results were similar to those previously reported for the antimetastic microRNA-335 (miR-335). Both TCDD and MCDF induced miR-335 in MDA-MB-231 and BT474 cells and this was accompanied by downregulation of SOX4, a miR-335-regulated (inhibited) gene. The effects of TCDD and MCDF on miR-335 and SOX4 expression and interactions of miR-335 with the 3'-UTR target sequence in the SOX4 gene were all inhibited in cells transfected with an oligonucleotide (iAHR) that knocks down the AHR, thus confirming AHR-miR-335 interactions. MCDF (40 mg/kg/d) also inhibited lung metastasis of MDA-MB-231 cells in a tail vein injection model, showing that the AHR is a potential new target for treating patients with ER-negative breast cancer, a disease where treatment options and their effectiveness are limited., (©2011 AACR.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.